This so-called Study 303 randomised 1,375 subjects to rimegepant 75 mg ODT or placebo, with which they treated 1 migraine attack of moderate or severe pain intensity. The coprimary endpoints were freedom of pain after 2 hours, and freedom from the most bothersome symptom. A total of 1,351 subjects were evaluated for efficacy. Rimegepant ODT was superior to placebo for 2-hour pain freedom (21.2% vs 10.9%; P<0.0001) and freedom from the most bothersome symptom (35.1% vs 26.8%; P=0.0009). Rimegepant ODT also significantly outperformed placebo for secondary endpoints like 60-minute pain relief, 48-hour sustained pain freedom, and (sustained) functional disability freedom. The most common adverse events were nausea and urinary tract infection, occurring in ≤1.6% of patients. There were no serious treatment-emergent adverse events.
1. Lipton RB, et al. AAN 2019, emerging science 005.
Posted on
Previous Article
« No increased MS relapse risk postpartum Next Article
Biotin, ocrelizumab, and ibudilast in progressive MS »
« No increased MS relapse risk postpartum Next Article
Biotin, ocrelizumab, and ibudilast in progressive MS »
Table of Contents: AAN 2019
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer's Disease and other Dementias
Amyloid PET in cognitively impaired patients
Tight blood pressure control lowers risk of mild cognitive impairment
Epilepsy
Headache and Migraine
Multiple Sclerosis and NMOSD
Immune tolerance by peptide-loaded tolerogenic dendritic cells
Biotin, ocrelizumab, and ibudilast in progressive MS
No increased MS relapse risk postpartum
Neuromuscular Disorders
First-ever effective and safe treatment of CMT1A
Parkinson’s Disease and other Movement Disorders
Leukaemia and hypertension therapies tested in Parkinson’s disease
Stroke
Miscellaneous
Possibly lifesaving therapy in refractory PML
New AAN guideline for treating Tourette syndrome
Subspecialty teleneurology: feasible and highly valued
Related Articles
July 30, 2019
Lasmiditan: rapid onset of efficacy in acute migraine
July 30, 2019
New formulation of rimegepant: fast onset of action
July 30, 2019
No increased MS relapse risk postpartum
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy